Drug screen conducted at SBP identifies new therapeutic avenues for Alzheimer?s disease

A screen of more than 1,600 Food and Drug Administration (FDA)?approved drugs performed at SBP?s Conrad Prebys Center for Chemical Genomics (Prebys Center) has revealed new therapeutic avenues that could lead to an Alzheimer?s disease treatment.?